These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 18329284)

  • 1. The hERG K+ channel: target and antitarget strategies in drug development.
    Raschi E; Vasina V; Poluzzi E; De Ponti F
    Pharmacol Res; 2008 Mar; 57(3):181-95. PubMed ID: 18329284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [HERG K+ channel, the target of anti-arrhythmias drugs].
    Guan FY; Yang SJ
    Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting drug-hERG channel interactions that cause acquired long QT syndrome.
    Sanguinetti MC; Mitcheson JS
    Trends Pharmacol Sci; 2005 Mar; 26(3):119-24. PubMed ID: 15749156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
    Thomas D; Karle CA; Kiehn J
    Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
    Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
    Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. hERG-related drug toxicity and models for predicting hERG liability and QT prolongation.
    Raschi E; Ceccarini L; De Ponti F; Recanatini M
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1005-21. PubMed ID: 19572824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.
    Deacon M; Singleton D; Szalkai N; Pasieczny R; Peacock C; Price D; Boyd J; Boyd H; Steidl-Nichols JV; Williams C
    J Pharmacol Toxicol Methods; 2007; 55(3):238-47. PubMed ID: 17141530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
    Towart R; Linders JT; Hermans AN; Rohrbacher J; van der Linde HJ; Ercken M; Cik M; Roevens P; Teisman A; Gallacher DJ
    J Pharmacol Toxicol Methods; 2009; 60(1):1-10. PubMed ID: 19439185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hERG potassium channel as a therapeutic target.
    Witchel HJ
    Expert Opin Ther Targets; 2007 Mar; 11(3):321-36. PubMed ID: 17298291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects.
    Zünkler BJ
    Pharmacol Ther; 2006 Oct; 112(1):12-37. PubMed ID: 16647758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lead compound optimization strategy(5) – reducing the hERG cardiac toxicity in drug development].
    Zhou SB; Wang J; Liu H
    Yao Xue Xue Bao; 2016 Oct; 51(10):1530-9. PubMed ID: 29932317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
    Polak S; Wiśniowska B; Brandys J
    J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
    Gintant GA; Su Z; Martin RL; Cox BF
    Toxicol Pathol; 2006; 34(1):81-90. PubMed ID: 16507548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. hERG: protein trafficking and potential for therapy and drug side effects.
    Staudacher I; Schweizer PA; Katus HA; Thomas D
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):23-30. PubMed ID: 20047143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interactions between hERG potassium channel and blockers.
    Du L; Li M; You Q
    Curr Top Med Chem; 2009; 9(4):330-8. PubMed ID: 19442204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of temperature-induced hERG channel blockade variation by drugs.
    Kauthale RR; Dadarkar SS; Husain R; Karande VV; Gatne MM
    J Appl Toxicol; 2015 Jul; 35(7):799-805. PubMed ID: 25348819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
    Hancox JC; McPate MJ; El Harchi A; Zhang YH
    Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
    Wiśniowska B; Mendyk A; Fijorek K; Glinka A; Polak S
    J Appl Toxicol; 2012 Oct; 32(10):858-66. PubMed ID: 22761000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of methadone and heroin on human ether-à-go-go-related gene channels.
    Zünkler BJ; Wos-Maganga M
    Cardiovasc Toxicol; 2010 Sep; 10(3):161-5. PubMed ID: 20467834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observations on conducting whole-cell patch clamping of the hERG cardiac K
    Kang J; Luo Y; Searles M; Rampe D
    J Appl Toxicol; 2017 Apr; 37(4):445-453. PubMed ID: 27553911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.